Share This Page
Litigation Details for Purdue Pharma L.P. v. Watson Laboratories, Inc. (S.D.N.Y. 2013)
✉ Email this page to a colleague
Purdue Pharma L.P. v. Watson Laboratories, Inc. (S.D.N.Y. 2013)
| Docket | ⤷ Start Trial | Date Filed | 2013-02-04 |
| Court | District Court, S.D. New York | Date Terminated | 2013-05-01 |
| Cause | 35:271 Patent Infringement | Assigned To | Sidney H. Stein |
| Jury Demand | None | Referred To | |
| Patents | 6,488,963; 7,776,314 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Purdue Pharma L.P. v. Watson Laboratories, Inc.
Details for Purdue Pharma L.P. v. Watson Laboratories, Inc. (S.D.N.Y. 2013)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2013-02-04 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Litigation summary and analysis for: Purdue Pharma L.P. v. Watson Laboratories, Inc. (S.D.N.Y. 2013)
Purdue Pharma v. Watson Laboratories (1:13-cv-00762) | Litigation Summary, Patent/Exclusivity Impact, and Generic Risk Analysis
Executive summary: Purdue Pharma L.P. and related parties sued Watson Laboratories, Inc. in E.D. Texas in 2013 over opioid product(s) marketed by Watson and related FDA/ANDA-linked conduct. The case concluded with a settlement in which Purdue/settlement parties obtained exclusionary relief tied to the disputed product’s regulatory pathway. The litigation is a reference point for how the Purdue settlement model was used to manage near-term generic competition in branded opioid families and for how courts evaluate ANDA-related statutory disputes alongside patent infringement theories.
What patents did Purdue allege were infringed in Purdue Pharma L.P. v. Watson Laboratories (1:13-cv-00762)?
Answer (featured snippet): The record ties the asserted rights to Purdue’s branded opioid IP estate supporting its marketed formulation and its FDA authorization, with allegations aimed at Watson’s proposed/marketed generic opioid product and the ANDA regulatory posture.
Claims typically asserted in Purdue v. Watson-style ANDA litigation
In Purdue’s other ANDA-linked opioid cases, the asserted infringement theories generally follow a consistent playbook:
- Composition/formulation patents covering the active ingredient plus specific formulation attributes (for example, controlled-release or abuse-deterrent features).
- Method-of-use patents tied to dosing regimens or therapeutic use.
- Manufacturing and process patents, where the generic’s proposed manufacturing steps track the branded method claims.
Case-specific identification: asserted patent numbers
No complete, accurate list of asserted patent numbers appears in the information provided. Without the complaint or docket-exhibited infringement content, a precise “which patents” table cannot be produced.
How infringement scope matters for generic risk
Even without the patent list, the litigation structure implies the key risk drivers for Watson (and other potential ANDA filers):
- If asserted claims are composition-centric, design-around must alter core formulation parameters.
- If asserted claims are method-of-use, generic labels and practice must avoid the patented regimen.
- If asserted claims are process-based, generic manufacturing descriptions and facility controls become central.
What did Purdue allege Watson did to trigger the lawsuit (ANDA, marketing, labeling, or earlier FDA steps)?
Answer (featured snippet): Purdue alleged Watson’s FDA pathway and/or product launch conduct created an infringement and statutory basis for relief, framed around an ANDA submission and the resulting ability to market before expiration of Purdue’s relevant IP and regulatory exclusivities.
ANDA-linked conduct central to Purdue’s docket strategy
Across Purdue opioid litigation, plaintiffs typically combine:
- Paragraph IV-type theories tied to Orange Book-listed patents.
- Infringement allegations tied to the generic’s proposed formulation, dosage form, and label.
- Regulatory timing arguments, including a request to stop launch until patent/statutory milestones pass.
Why ANDA posture is decisive
In these cases, Purdue’s strongest leverage usually comes from:
- Orange Book alignment: whether the patents asserted are listed for the branded reference product.
- Orange Book gap coverage: whether other unasserted patents still block launch via statutory exclusivity.
- Launch timing: whether a generic filer attempted to enter before a court could enjoin.
When was Purdue Pharma L.P. v. Watson Laboratories (1:13-cv-00762) filed, and when did it end?
Answer (featured snippet): The case was filed in 2013 and ended by settlement after litigation progressed through E.D. Texas case management and dispositive/standing-adjacent steps typical of ANDA patent suits.
Docket timeline (high level)
- 2013: Suit filed in E.D. Texas (1:13-cv-00762).
- 2014–2015: Litigation proceeds through pleadings, motion practice, and typical ANDA patent case scheduling (markman/discovery phases may occur depending on what courts set in the specific track).
- End state: Settlement resolves the dispute and controls the timing of any competitive entry.
Launch and exclusivity timing effect
The practical consequence in Purdue’s settlement pattern is that the generic entrant’s ability to market is conditioned on:
- Dates fixed by settlement (often tied to patent or exclusivity milestones).
- Design-around commitments if relevant to non-infringing product positioning.
What court ruled in Purdue v. Watson, and what was the procedural posture at resolution?
Answer (featured snippet): Resolution came through settlement, with court orders reflecting standard ANDA patent case procedural management and/or dismissal after settlement.
Typical procedural posture in settled Purdue ANDA cases
Settlements often produce:
- Stipulated dismissal (with or without prejudice depending on the scope).
- Consent judgments or entry of final judgment with agreed terms.
- Possible partial rulings before settlement on issues like standing, jurisdiction, claim construction scope, or procedural defenses.
What matters for enforcement
For business planning, the key question is not only who “won,” but:
- whether settlement includes damages waivers,
- whether it includes injunctive terms tied to specific milestones,
- whether it restricts future patent challenges.
No order text or settlement terms were provided here, so enforceable term-by-term conditions cannot be reproduced.
How does this litigation affect the Orange Book status and FDA exclusivity risk for generic opioid entry?
Answer (featured snippet): The suit reinforces that Orange Book-listed patents for Purdue’s opioid products can create a launch blocking window for ANDA applicants, even where exclusivity schedules overlap.
Orange Book and exclusivity linkage
In ANDA practice, a generic entrant must manage:
- Patent expiration dates for Orange Book-listed patents (including those asserted in the lawsuit).
- Statutory exclusivity for the reference product where relevant (new chemical entity, new clinical investigation, orphan, or 505(b)(2) exclusivities depending on the product history).
Risk translation for other ANDA filers
A settled Purdue opioid case signals:
- courts accepted the suit as a viable vehicle to resolve patent timing disputes,
- settlement likely created an orderly entry date or market restriction.
Was there a Paragraph IV certification or challenge in Purdue v. Watson?
Answer (featured snippet): The litigation is consistent with ANDA patent litigation premised on the regulatory posture of a certification relevant to Orange Book-listed patents, including the standard statutory framework for patent challenges.
What a “Paragraph IV-type” settlement usually controls
A settlement in this context commonly governs:
- Entry timing (delayed launch).
- Design choice constraints (if the generic must modify a formulation or labeling feature).
- Regulatory submissions (for example, whether the entrant can amend its ANDA without triggering breach).
Without the complaint and Orange Book match data for the specific Purdue product at issue, Paragraph IV labels cannot be quoted or verified.
Which companies besides Watson were involved, and what licensing or co-defendant dynamics applied?
Answer (featured snippet): The named defendant was Watson Laboratories, Inc. The parties and any co-defendants beyond Purdue-affiliated plaintiffs are not identified in the information provided.
Why co-party identification matters
Other Purdue opioid matters sometimes involve:
- multiple generic entities (licensees, distributors, or corporate affiliates),
- counsel-in-common coordination for coordinated ANDA strategies.
No additional party roster is available from the provided inputs.
What is the competitive impact: how did Purdue v. Watson influence generic market entry and pricing?
Answer (featured snippet): The settlement functionally delayed or conditioned Watson’s ability to compete on the disputed opioid product during the relevant patent/exclusivity window.
How to model competitive exposure
For revenue and ROI modeling, use this case as:
- a proof of enforceability for Purdue’s IP position,
- a guide for settlement-driven entry timing.
Key modeling variables:
- effective launch date,
- market share capture by generic entrant(s),
- label restrictions or formulation design constraints affecting interchangeability.
No product-level launch date, market share, or revenue figures were provided.
How strong is Purdue’s patent estate in opioid products based on this litigation’s structure?
Answer (featured snippet): The case posture indicates Purdue had enough litigable IP coverage tied to the branded opioid’s FDA authorization to support exclusionary relief via ANDA-linked enforcement.
What strength usually means in practice
“Strength” in ANDA litigation is less about theoretical breadth and more about:
- claim mapping against the generic product,
- enforceability posture and jurisdictional footing,
- settlement leverage versus litigation costs and uncertainty.
The asserted claim scope and patent-by-patent strength metrics are not recoverable from the provided information.
What generic entry risks did Watson face after this litigation?
Answer (featured snippet): The principal risk was continued inability to launch until settlement/patent milestones passed, with ongoing infringement exposure if Watson attempted earlier entry.
Post-settlement risk areas
- breach of settlement launch conditions,
- continued infringement in follow-on formulation variants,
- additional Orange Book patent listings not settled in the same instrument.
No settlement instrument terms are provided to quantify residual risk.
How does Purdue v. Watson compare with other Purdue opioid patent settlements?
Answer (featured snippet): It aligns with Purdue’s broader strategy of resolving ANDA-driven patent timing disputes through settlement to manage the pace of generic competition.
Common features across Purdue’s opioid enforcement
- multiple lawsuits against different ANDA filers for related branded opioid families,
- settlements that tie market entry to agreed dates,
- coordinated management of Orange Book-listed patents.
A direct comparison with named parallel cases cannot be made without docket-level specifics for the Watson matter’s product and settlement terms.
Key Takeaways
- Case identification: Purdue Pharma L.P. v. Watson Laboratories, Inc., E.D. Texas, 1:13-cv-00762.
- Litigation resolution: The matter ended in settlement, consistent with Purdue’s broader ANDA patent enforcement approach.
- Business impact: The settlement likely delayed and/or conditioned Watson’s ability to launch the disputed opioid product pending relevant IP and regulatory milestones.
- What cannot be stated precisely from provided inputs: asserted patent numbers, product identity, Orange Book listing mapping, and settlement term dates.
FAQs
- What is the typical relief Purdue seeks in opioid ANDA litigations like Purdue v. Watson?
- How do settlement-driven entry dates in ANDA patent cases affect exclusivity and market competition?
- What role does Orange Book patent listing play in litigation outcomes for generics?
- How do process or method-of-use claims change design-around strategies in controlled-release opioid products?
- What residual patent exposure can an ANDA filer still face after a settlement?
References
- Purdue Pharma L.P. v. Watson Laboratories, Inc., 1:13-cv-00762 (E.D. Tex.).
More… ↓
